Net loss $17.4M in Q3; cash $290.2M; SL-172154/SL-279252 Phase 1 data; Takeda deal terminated

Shattuck Labs, Inc.

2021-Q3 EPS reported -$1.26 revenue$-61,000

Net loss $17.4M ($0.41/share) vs $11.8M ($1.54/share) in Q3 2020; cash $290.2M, down from $335.4M.
SL-172154 Phase 1 in ovarian cancer well-tolerated with high CD47 occupancy; dose escalation continues to 10mg/kg.
SL-279252 Phase 1 in solid tumors: one confirmed partial response, stable disease in 12 of 43 patients.
Shattuck and Takeda mutually terminated collaboration; Shattuck regains full rights to SL-279252 and SL-115154.
Cash runway sufficient into H2 2024; guidance reduced due to increased SL-172154 clinical and manufacturing costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.